Importer of Controlled Substances Application: Lipomed, 31622-31627 [2019-14026]
Download as PDF
<![CDATA[
31622
Federal Register / Vol. 84, No. 127 / Tuesday, July 2, 2019 / Notices
Administration (DEA) as importer of
schedule I controlled substances.
SUPPLEMENTARY INFORMATION: The
company listed below applied to be
registered as an importer of basic class
of controlled substances. Information on
previously published notice is listed in
the table below. No comments or
objections were submitted and no
requests for a hearing were submitted
for this notice.
FR
Docket
Company
Sharp (Bethlehem),
LLC.
84 FR
9837.
Published
March 18,
2019
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of the
listed registrant to import the applicable
basic class of schedule I controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. The DEA investigated the
company’s maintenance of effective
controls against diversion by inspecting
and testing the company’s physical
security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule I controlled substances to the
above listed company.
Dated: June 3, 2019.
John J. Martin,
Assistant Administrator.
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on April 17, 2019,
Bellwyck Clinical Services, 8946 Global
Way, West Chester, Ohio 45069 applied
to be registered as an importer of the
following basic class of controlled
substances:
Controlled
substance
Drug code
Amphetamine ...
Methylphenidate
Oxycodone .......
1100
1724
9143
Schedule
II
II
II
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
[Docket No. DEA–392]
Drug Enforcement Administration
Importer of Controlled Substances
Application: Bellwyck Clinical Services
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 1, 2019. Such persons
may also file a written request for a
hearing on the application on or before
August 1, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
khammond on DSKBBV9HB2PROD with NOTICES
DATES:
VerDate Sep<11>2014
17:00 Jul 01, 2019
Jkt 247001
Controlled
substance
Drug code
Difenoxin ...........
Diphenoxylate ...
Levorphanol ......
Meperidine intermediate-B.
9168
9170
9220
9233
Schedule
I
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Dated: June 19, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–14028 Filed 7–1–19; 8:45 am]
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Pisgah
Laboratories, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before September 3, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
DATES:
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Lipomed
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 1, 2019. Such persons
may also file a written request for a
hearing on the application on or before
August 1, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
DATES:
[FR Doc. 2019–14027 Filed 7–1–19; 8:45 am]
Drug Enforcement Administration
In
accordance with 21 CFR 1301.33(a), this
is notice that on March 5, 2019, Pisgah
Laboratories, Inc., 3222 Old
Hendersonville Highway, Pisgah Forest,
North Carolina 28768 applied to be
registered as a bulk manufacturer of the
following basic classes of controlled
substances:
SUPPLEMENTARY INFORMATION:
BILLING CODE 4410–09–P
The company plans to import the
listed controlled substances in dosage
form to conduct clinical trials. Approval
of permit applications will occur only
when the registrant’s activity is
consistent with what is authorized
under 21 U.S.C. 952(a) (2).
Authorization will not extend to the
import of FDA approved or nonapproved finished dosage forms for
commercial sale.
Dated: June 18, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–14023 Filed 7–1–19; 8:45 am]
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
E:\FR\FM\02JYN1.SGM
02JYN1
31623
Federal Register / Vol. 84, No. 127 / Tuesday, July 2, 2019 / Notices
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on March 28, 2019,
Lipomed, 150 Cambridge Park Drive,
SUPPLEMENTARY INFORMATION:
Suite 705, Cambridge, Massachusetts
02140 applied to be registered as an
importer of the following basic classes
of controlled substances:
khammond on DSKBBV9HB2PROD with NOTICES
Controlled substance
Drug code
3-Fluoro-N-methylcathinone (3–FMC) .............................................................................................................................
Cathinone ........................................................................................................................................................................
Methcathinone .................................................................................................................................................................
4-Fluoro-N-methylcathinone (4–FMC) .............................................................................................................................
Pentedrone (a-methylaminovalerophenone) ...................................................................................................................
Mephedrone (4-Methyl-N-methylcathinone) ....................................................................................................................
4-Methyl-N-ethylcathinone (4–MEC) ...............................................................................................................................
Naphyrone .......................................................................................................................................................................
N-Ethylamphetamine .......................................................................................................................................................
N,N-Dimethylamphetamine ..............................................................................................................................................
Fenethylline .....................................................................................................................................................................
Aminorex ..........................................................................................................................................................................
4-Methylaminorex (cis isomer) ........................................................................................................................................
Gamma Hydroxybutyric Acid ...........................................................................................................................................
Methaqualone ..................................................................................................................................................................
Mecloqualone ..................................................................................................................................................................
JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) ..................................................................................................
SR–18 (Also known as RCS–8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ................................................
ADB–FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .............
5-Fluoro-UR–144 and XLR11 ([1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone) .............
AB–FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .....................
JWH–019 (1-Hexyl-3-(1-naphthoyl)indole) ......................................................................................................................
MDMB–FUBINACA (Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ......................
FUB–AMB, MMB–FUBINACA, AMB–FUBINACA (2-(1-(4-fluorobenzyl)-1Hindazole-3-carboxamido)-3methylbutanoate).
AB–PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .........................................
THJ–2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) .................................................................
5F–AB–PINACA (N-(1-amino-3methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) ......................
AB–CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) ...............
MAB–CHMINACA (N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) ........
5F–AMB (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) ..............................................
5F–ADB; 5F–MDMB–PINACA (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ......
ADB–PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .................................
MDMB–CHMICA, MMB–CHMINACA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3dimethylbutanoate).
MMB–CHMICA , AMB–CHMICA (methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate) ......
APINACA and AKB48 (N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide) ............................................................
5F–APINACA, 5F–AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) ..................................
JWH–081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) ..................................................................................................
5F–CUMYL–P7AICA (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide) ...............
4–CN–CUMYL–BUTINACA, 4-cyano-CUMYL–BUTINACA, 4–CN–CUMYL BINACA, CUMYL–4CN–BINACA, SGT–
78 (1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboximide).
SR–19 (Also known as RCS–4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole) ...................................................................
JWH–018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) ..............................................................................
JWH–122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) .....................................................................................................
UR–144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone) ................................................................
JWH–073 (1-Butyl-3-(1-naphthoyl)indole) .......................................................................................................................
JWH–200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) ..........................................................................................
AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) .......................................................................................................
JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) ......................................................................................................
NM2201, CBL2201 (Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) .........................................................
PB–22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) .................................................................................................
5F–PB–22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) ............................................................................
Alpha-ethyltryptamine ......................................................................................................................................................
Ibogaine ...........................................................................................................................................................................
CP–47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) ................................................................
CP–47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol) ..........................................
Lysergic acid diethylamide ..............................................................................................................................................
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C–T–7) ..............................................................................................
Marihuana extract ............................................................................................................................................................
Marihuana ........................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
Parahexyl .........................................................................................................................................................................
Mescaline .........................................................................................................................................................................
2C–T–2, (2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine) ..........................................................................................
3,4,5-Trimethoxyamphetamine ........................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine .............................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine ..........................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine .............................................................................................................................
VerDate Sep<11>2014
17:00 Jul 01, 2019
Jkt 247001
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
E:\FR\FM\02JYN1.SGM
02JYN1
Schedule
1233
1235
1237
1238
1246
1248
1249
1258
1475
1480
1503
1585
1590
2010
2565
2572
6250
7008
7010
7011
7012
7019
7020
7021
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
7023
7024
7025
7031
7032
7033
7034
7035
7042
I
I
I
I
I
I
I
I
I
7044
7048
7049
7081
7085
7089
I
I
I
I
I
I
7104
7118
7122
7144
7173
7200
7201
7203
7221
7222
7225
7249
7260
7297
7298
7315
7348
7350
7360
7370
7374
7381
7385
7390
7391
7392
7395
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
31624
Federal Register / Vol. 84, No. 127 / Tuesday, July 2, 2019 / Notices
khammond on DSKBBV9HB2PROD with NOTICES
Controlled substance
Drug code
2,5-Dimethoxyamphetamine ............................................................................................................................................
JWH–398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole) ......................................................................................................
2,5-Dimethoxy-4-ethylamphetamine ................................................................................................................................
3,4-Methylenedioxyamphetamine ....................................................................................................................................
5-Methoxy-3,4-methylenedioxyamphetamine ..................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ..................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine .......................................................................................................................
3,4-Methylenedioxymethamphetamine ............................................................................................................................
4-Methoxyamphetamine ..................................................................................................................................................
5-Methoxy-N–N-dimethyltryptamine ................................................................................................................................
Alpha-methyltryptamine ...................................................................................................................................................
Bufotenine ........................................................................................................................................................................
Diethyltryptamine .............................................................................................................................................................
Dimethyltryptamine ..........................................................................................................................................................
Psilocybin .........................................................................................................................................................................
Psilocyn ...........................................................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine .............................................................................................................................
N-Ethyl-1-phenylcyclohexylamine ....................................................................................................................................
1-(1-Phenylcyclohexyl)pyrrolidine ....................................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine ...............................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine ..............................................................................................................................
N-Ethyl-3-piperidyl benzilate ............................................................................................................................................
N-Methyl-3-piperidyl benzilate .........................................................................................................................................
N-Benzylpiperazine ..........................................................................................................................................................
4-MePPP (4-Methyl-alphapyrrolidinopropiophenone) .....................................................................................................
2C–D (2-(2,5-Dimethoxy-4-methylphenyl) ethanamine) ..................................................................................................
2C–E (2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine) .....................................................................................................
2C–H (2-(2,5-Dimethoxyphenyl) ethanamine) .................................................................................................................
2C–I (2-(4-iodo-2,5-dimethoxyphenyl) ethanamine) ........................................................................................................
2C–C (2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine) ..................................................................................................
2C–N (2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine) ....................................................................................................
2C–P (2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine) .............................................................................................
2C–T–4 (2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine) ....................................................................................
MDPV (3,4-Methylenedioxypyrovalerone) .......................................................................................................................
25B–NBOMe (2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine) ....................................................
25C–NBOMe (2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine) ....................................................
25I–NBOMe (2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine) .........................................................
Methylone (3,4-Methylenedioxy-N-methylcathinone) ......................................................................................................
Butylone ...........................................................................................................................................................................
Pentylone .........................................................................................................................................................................
N-Ethylpentylone, ephylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one) ....................................................
a-PVP (alpha-pyrrolidinopentiophenone) ........................................................................................................................
a-PBP (alpha-pyrrolidinobutiophenone) ..........................................................................................................................
AM–694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole) ...................................................................................................
Acetyldihydrocodeine .......................................................................................................................................................
Benzylmorphine ...............................................................................................................................................................
Codeine-N-oxide ..............................................................................................................................................................
Cyprenorphine .................................................................................................................................................................
Desomorphine .................................................................................................................................................................
Etorphine (except HCl) ....................................................................................................................................................
Codeine methylbromide ...................................................................................................................................................
Dihydromorphine .............................................................................................................................................................
Difenoxin ..........................................................................................................................................................................
Heroin ..............................................................................................................................................................................
Hydromorphinol ...............................................................................................................................................................
Methyldesorphine ............................................................................................................................................................
Methyldihydromorphine ...................................................................................................................................................
Morphine methylbromide .................................................................................................................................................
Morphine methylsulfonate ...............................................................................................................................................
Morphine-N-oxide ............................................................................................................................................................
Myrophine ........................................................................................................................................................................
Nicocodeine .....................................................................................................................................................................
Nicomorphine ...................................................................................................................................................................
Normorphine ....................................................................................................................................................................
Pholcodine .......................................................................................................................................................................
Thebacon .........................................................................................................................................................................
Acetorphine ......................................................................................................................................................................
Drotebanol .......................................................................................................................................................................
U–47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide) ..............................................................
AH–7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)) ..................................................................
MT–45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine)) ..................................................................................................
Acetylmethadol ................................................................................................................................................................
Allylprodine ......................................................................................................................................................................
Alphacetylmethadol except levo-alphacetylmethadol ......................................................................................................
VerDate Sep<11>2014
17:00 Jul 01, 2019
Jkt 247001
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
E:\FR\FM\02JYN1.SGM
02JYN1
7396
7398
7399
7400
7401
7402
7404
7405
7411
7431
7432
7433
7434
7435
7437
7438
7439
7455
7458
7470
7473
7482
7484
7493
7498
7508
7509
7517
7518
7519
7521
7524
7532
7535
7536
7537
7538
7540
7541
7542
7543
7545
7546
7694
9051
9052
9053
9054
9055
9056
9070
9145
9168
9200
9301
9302
9304
9305
9306
9307
9308
9309
9312
9313
9314
9315
9319
9335
9547
9551
9560
9601
9602
9603
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
31625
Federal Register / Vol. 84, No. 127 / Tuesday, July 2, 2019 / Notices
khammond on DSKBBV9HB2PROD with NOTICES
Controlled substance
Drug code
Alphameprodine ...............................................................................................................................................................
Alphamethadol .................................................................................................................................................................
Benzethidine ....................................................................................................................................................................
Betacetylmethadol ...........................................................................................................................................................
Betameprodine ................................................................................................................................................................
Betamethadol ...................................................................................................................................................................
Betaprodine .....................................................................................................................................................................
Clonitazene ......................................................................................................................................................................
Dextromoramide ..............................................................................................................................................................
Diampromide ...................................................................................................................................................................
Diethylthiambutene ..........................................................................................................................................................
Dimenoxadol ....................................................................................................................................................................
Dimepheptanol .................................................................................................................................................................
Dimethylthiambutene .......................................................................................................................................................
Dioxaphetyl butyrate ........................................................................................................................................................
Dipipanone .......................................................................................................................................................................
Ethylmethylthiambutene ..................................................................................................................................................
Etonitazene ......................................................................................................................................................................
Etoxeridine .......................................................................................................................................................................
Furethidine .......................................................................................................................................................................
Hydroxypethidine .............................................................................................................................................................
Ketobemidone ..................................................................................................................................................................
Levomoramide .................................................................................................................................................................
Levophenacylmorphan ....................................................................................................................................................
Morpheridine ....................................................................................................................................................................
Noracymethadol ...............................................................................................................................................................
Norlevorphanol ................................................................................................................................................................
Normethadone .................................................................................................................................................................
Norpipanone ....................................................................................................................................................................
Phenadoxone ...................................................................................................................................................................
Phenampromide ..............................................................................................................................................................
Phenoperidine ..................................................................................................................................................................
Piritramide ........................................................................................................................................................................
Proheptazine ....................................................................................................................................................................
Properidine ......................................................................................................................................................................
Racemoramide ................................................................................................................................................................
Trimeperidine ...................................................................................................................................................................
Phenomorphan ................................................................................................................................................................
Propiram ..........................................................................................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine ......................................................................................................................
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine ..............................................................................................................
Tilidine .............................................................................................................................................................................
Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) .................................................................................
Para-Fluorofentanyl .........................................................................................................................................................
3-Methylfentanyl ..............................................................................................................................................................
Alpha-Methylfentanyl .......................................................................................................................................................
Acetyl-alpha-methylfentanyl .............................................................................................................................................
N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide .......................................................................................
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) ...............................................................................
Butyryl Fentanyl ...............................................................................................................................................................
Para-fluorobutyryl fentanyl ...............................................................................................................................................
4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide) .........................................
2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide .........................................................................................
Para-chloroisobutyryl fentanyl .........................................................................................................................................
Isobutyryl fentanyl ............................................................................................................................................................
Beta-hydroxyfentanyl .......................................................................................................................................................
Beta-hydroxy-3-methylfentanyl ........................................................................................................................................
Alpha-methylthiofentanyl .................................................................................................................................................
3-Methylthiofentanyl .........................................................................................................................................................
Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide) .............................................................
Thiofentanyl .....................................................................................................................................................................
Beta-hydroxythiofentanyl .................................................................................................................................................
Para-methoxybutyryl fentanyl ..........................................................................................................................................
Ocfentanil .........................................................................................................................................................................
Valeryl fentanyl ................................................................................................................................................................
N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide) .........................................................................
Cyclopropyl Fentanyl .......................................................................................................................................................
Cyclopentyl fentanyl ........................................................................................................................................................
Fentanyl related-compounds as defined in 21 CFR 1308.11(h) .....................................................................................
Amphetamine ...................................................................................................................................................................
Methamphetamine ...........................................................................................................................................................
Lisdexamfetamine ............................................................................................................................................................
Phenmetrazine .................................................................................................................................................................
Methylphenidate ..............................................................................................................................................................
VerDate Sep<11>2014
17:00 Jul 01, 2019
Jkt 247001
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
E:\FR\FM\02JYN1.SGM
02JYN1
9604
9605
9606
9607
9608
9609
9611
9612
9613
9615
9616
9617
9618
9619
9621
9622
9623
9624
9625
9626
9627
9628
9629
9631
9632
9633
9634
9635
9636
9637
9638
9641
9642
9643
9644
9645
9646
9647
9649
9661
9663
9750
9811
9812
9813
9814
9815
9816
9821
9822
9823
9824
9825
9826
9827
9830
9831
9832
9833
9834
9835
9836
9837
9838
9840
9843
9845
9847
9850
1100
1105
1205
1631
1724
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
31626
Federal Register / Vol. 84, No. 127 / Tuesday, July 2, 2019 / Notices
Controlled substance
Drug code
khammond on DSKBBV9HB2PROD with NOTICES
Amobarbital ......................................................................................................................................................................
Pentobarbital ....................................................................................................................................................................
Secobarbital .....................................................................................................................................................................
Glutethimide .....................................................................................................................................................................
Dronabinol in an oral solution in a drug product approved for marketing by the U.S. Food and Drug Administration
Nabilone ...........................................................................................................................................................................
1-Phenylcyclohexylamine ................................................................................................................................................
Phencyclidine ...................................................................................................................................................................
ANPP (4-Anilino-N-phenethyl-4-piperidine) .....................................................................................................................
Phenylacetone .................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ................................................................................................................................
Alphaprodine ....................................................................................................................................................................
Anileridine ........................................................................................................................................................................
Cocaine ............................................................................................................................................................................
Codeine ...........................................................................................................................................................................
Etorphine HCl ..................................................................................................................................................................
Dihydrocodeine ................................................................................................................................................................
Oxycodone .......................................................................................................................................................................
Hydromorphone ...............................................................................................................................................................
Diphenoxylate ..................................................................................................................................................................
Ecgonine ..........................................................................................................................................................................
Ethylmorphine ..................................................................................................................................................................
Hydrocodone ...................................................................................................................................................................
Levomethorphan ..............................................................................................................................................................
Levorphanol .....................................................................................................................................................................
Isomethadone ..................................................................................................................................................................
Meperidine .......................................................................................................................................................................
Meperidine-intermediate-A ..............................................................................................................................................
Meperidine intermediate-B ..............................................................................................................................................
Meperidine intermediate-C ..............................................................................................................................................
Metazocine ......................................................................................................................................................................
Methadone .......................................................................................................................................................................
Methadone intermediate ..................................................................................................................................................
Metopon ...........................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ..............................................................................................................
Morphine ..........................................................................................................................................................................
Oripavine .........................................................................................................................................................................
Thebaine ..........................................................................................................................................................................
Dihydroetorphine .............................................................................................................................................................
Levo-alphacetylmethadol .................................................................................................................................................
Oxymorphone ..................................................................................................................................................................
Noroxymorphone .............................................................................................................................................................
Phenazocine ....................................................................................................................................................................
Thiafentanil ......................................................................................................................................................................
Piminodine .......................................................................................................................................................................
Racemethorphan .............................................................................................................................................................
Racemorphan ..................................................................................................................................................................
Alfentanil ..........................................................................................................................................................................
Remifentanil .....................................................................................................................................................................
Sufentanil .........................................................................................................................................................................
Carfentanil .......................................................................................................................................................................
Tapentadol .......................................................................................................................................................................
Bezitramide ......................................................................................................................................................................
Fentanyl ...........................................................................................................................................................................
Moramide-intermediate ....................................................................................................................................................
VerDate Sep<11>2014
17:00 Jul 01, 2019
Jkt 247001
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
E:\FR\FM\02JYN1.SGM
02JYN1
2125
2270
2315
2550
7365
7379
7460
7471
8333
8501
8603
9010
9020
9041
9050
9059
9120
9143
9150
9170
9180
9190
9193
9210
9220
9226
9230
9232
9233
9234
9240
9250
9254
9260
9273
9300
9330
9333
9334
9648
9652
9668
9715
9729
9730
9732
9733
9737
9739
9740
9743
9780
9800
9801
9802
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Federal Register / Vol. 84, No. 127 / Tuesday, July 2, 2019 / Notices
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytical purposes. Placement of
these drug codes onto the company’s
registration does not translate into
automatic approval of subsequent
permit applications to import controlled
substances. Approval of permit
applications will occur only when the
registrant’s business activity is
consistent with what is authorized in 21
U.S.C. 952(a)(2). Authorization will not
extend to the import of FDA approved
or non-approved finished dosage forms
for commercial sale.
Dated: June 18, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–14026 Filed 7–1–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[OMB Number 1125–0001]
Agency Information Collection
Activities; Proposed Collection;
Comments Requested; Application for
Cancellation of Removal (42A) for
Certain Permanent Residents; and
Application for Cancellation of
Removal and Adjustment of Status
(42B) for Certain Nonpermanent
Residents
AGENCY:
Overview of This Information
Collection
The Department of Justice
(DOJ), Executive Office for Immigration
Review, will be submitting the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for an additional 30
days until August 1, 2019.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Lauren Alder Reid, Assistant Director,
Office of Policy, Executive Office for
Immigration Review, 5107 Leesburg
Pike, Suite 2500, Falls Church, VA
22041, telephone: (703) 305–0289.
Written comments and/or suggestions
can also be directed to the Office of
Management and Budget, Office of
1. Type of Information Collection:
Extension with changes to a currently
approved collection.
2. The Title of the Form/Collection:
Application for Cancellation of Removal
for Certain Permanent Residents; and
Application for Cancellation of Removal
and Adjustment of Status for Certain
Nonpermanent Residents.
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
The form numbers are EOIR–42A and
EOIR–42B, Executive Office for
Immigration Review, United States
Department of Justice.
4. Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: Individual aliens
determined to be removable from the
United States. Other: None. Abstract:
This information collection is necessary
to determine the statutory eligibility of
individual aliens who have been
determined to be removable from the
United States for cancellation of their
removal, as well as to provide
information relevant to a favorable
exercise of discretion.
5. An estimate of the total number of
respondents and the amount of time
Executive Office for
Immigration Review, Department of
Justice.
ACTION: 30-Day notice.
SUMMARY:
khammond on DSKBBV9HB2PROD with NOTICES
Information and Regulatory Affairs,
Attention Department of Justice Desk
Officer, Washington, DC 20530 or sent
to OIRA_submissions@omb.eop.gov.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Enhance the quality, utility, and
clarity of the information to be
collected; and/or
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
VerDate Sep<11>2014
17:00 Jul 01, 2019
Jkt 247001
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
31627
estimated for an average respondent to
respond: It is estimated that 27,999
respondents will complete the form
annually with an average of 5 hours and
50 minutes per response.
6. An estimate of the total public
burden (in hours) associated with the
collection: The estimated public burden
associated with this collection is
162,394 hours.
If additional information is required
contact: Melody Braswell, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE, 3E.405B,
Washington, DC 20530.
Dated: June 27, 2019.
Melody D. Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2019–14064 Filed 7–1–19; 8:45 am]
BILLING CODE 4410–30–P
NUCLEAR REGULATORY
COMMISSION
[Docket Nos. 52–025 and 52–026; NRC–
2008–0252]
Southern Nuclear Operating Company,
Inc.; Vogtle Electric Generating Plant,
Units 3 and 4; Passive Residual Heat
Removal Instrumentation Minimum
Inventory Displays
Nuclear Regulatory
Commission.
ACTION: Exemption and combined
license amendment; issuance.
AGENCY:
The U.S. Nuclear Regulatory
Commission (NRC) is granting an
exemption to allow a departure from the
certification information of Tier 1 of the
generic design control document (DCD)
and is issuing License Amendment Nos.
162 and 160 to Combined Licenses
(COLs), NPF–91 and NPF–92. The COLs
were issued to Southern Nuclear
Operating Company, Inc., and Georgia
Power Company, Oglethorpe Power
Corporation, MEAG Power SPVM, LLC,
MEAG Power SPVJ, LLC, MEAG Power
SPVP, LLC, and the City of Dalton,
Georgia (collectively SNC); for
construction and operation of the Vogtle
Electric Generating Plant (VEGP) Units
3 and 4, located in Burke County,
Georgia.
The granting of the exemption allows
the changes to Tier 1 information asked
for in the amendment. Because the
acceptability of the exemption was
determined in part by the acceptability
of the amendment, the exemption and
SUMMARY:
E:\FR\FM\02JYN1.SGM
02JYN1
]]>Agencies
[Federal Register Volume 84, Number 127 (Tuesday, July 2, 2019)]
[Notices]
[Pages 31622-31627]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-14026]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Lipomed
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before August 1, 2019. Such
persons may also file a written request for a hearing on the
application on or before August 1, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register
[[Page 31623]]
Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on March 28, 2019, Lipomed, 150 Cambridge Park Drive,
Suite 705, Cambridge, Massachusetts 02140 applied to be registered as
an importer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
3-Fluoro-N-methylcathinone (3-FMC)....... 1233 I
Cathinone................................ 1235 I
Methcathinone............................ 1237 I
4-Fluoro-N-methylcathinone (4-FMC)....... 1238 I
Pentedrone ([alpha]- 1246 I
methylaminovalerophenone).
Mephedrone (4-Methyl-N-methylcathinone).. 1248 I
4-Methyl-N-ethylcathinone (4-MEC)........ 1249 I
Naphyrone................................ 1258 I
N-Ethylamphetamine....................... 1475 I
N,N-Dimethylamphetamine.................. 1480 I
Fenethylline............................. 1503 I
Aminorex................................. 1585 I
4-Methylaminorex (cis isomer)............ 1590 I
Gamma Hydroxybutyric Acid................ 2010 I
Methaqualone............................. 2565 I
Mecloqualone............................. 2572 I
JWH-250 (1-Pentyl-3-(2- 6250 I
methoxyphenylacetyl) indole).
SR-18 (Also known as RCS-8) (1- 7008 I
Cyclohexylethyl-3-(2-
methoxyphenylacetyl) indole).
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1- 7010 I
oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-
indazole-3-carboxamide).
5-Fluoro-UR-144 and XLR11 ([1-(5-Fluoro- 7011 I
pentyl)1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone).
AB-FUBINACA (N-(1-amino-3-methyl-1- 7012 I
oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-
indazole-3-carboxamide).
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).. 7019 I
MDMB-FUBINACA (Methyl 2-(1-(4- 7020 I
fluorobenzyl)-1H-indazole-3-carboxamido)-
3,3-dimethylbutanoate).
FUB-AMB, MMB-FUBINACA, AMB-FUBINACA (2-(1- 7021 I
(4-fluorobenzyl)-1Hindazole-3-
carboxamido)-3-methylbutanoate).
AB-PINACA (N-(1-amino-3-methyl-1-oxobutan- 7023 I
2-yl)-1-pentyl-1H-indazole-3-
carboxamide).
THJ-2201 ([1-(5-fluoropentyl)-1H-indazol- 7024 I
3-yl](naphthalen-1-yl)methanone).
5F-AB-PINACA (N-(1-amino-3methyl-1- 7025 I
oxobutan-2-yl)-1-(5-fluoropentyl)-1H-
indazole-3-carboxamide).
AB-CHMINACA (N-(1-amino-3-methyl-1- 7031 I
oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-
indazole-3-carboxamide).
MAB-CHMINACA (N-(1-amino-3,3dimethyl-1- 7032 I
oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-
indazole-3-carboxamide).
5F-AMB (Methyl 2-(1-(5-fluoropentyl)-1H- 7033 I
indazole-3-carboxamido)-3-
methylbutanoate).
5F-ADB; 5F-MDMB-PINACA (Methyl 2-(1-(5- 7034 I
fluoropentyl)-1H-indazole-3-carboxamido)-
3,3-dimethylbutanoate).
ADB-PINACA (N-(1-amino-3,3-dimethyl-1- 7035 I
oxobutan-2-yl)-1-pentyl-1H-indazole-3-
carboxamide).
MDMB-CHMICA, MMB-CHMINACA (Methyl 2-(1- 7042 I
(cyclohexylmethyl)-1H-indole-3-
carboxamido)-3,3-dimethylbutanoate).
MMB-CHMICA , AMB-CHMICA (methyl 2-(1- 7044 I
(cyclohexylmethyl)-1H-indole-3-
carboxamido)-3-methylbutanoate).
APINACA and AKB48 (N-(1-Adamantyl)-1- 7048 I
pentyl-1H-indazole-3-carboxamide).
5F-APINACA, 5F-AKB48 (N-(adamantan-1-yl)- 7049 I
1-(5-fluoropentyl)-1H-indazole-3-
carboxamide).
JWH-081 (1-Pentyl-3-(1-(4- 7081 I
methoxynaphthoyl) indole).
5F-CUMYL-P7AICA (1-(5-fluoropentyl)-N-(2- 7085 I
phenylpropan-2-yl)-1H-pyrrolo[2,3-
b]pyridine-3-carboxamide).
4-CN-CUMYL-BUTINACA, 4-cyano-CUMYL- 7089 I
BUTINACA, 4-CN-CUMYL BINACA, CUMYL-4CN-
BINACA, SGT-78 (1-(4-cyanobutyl)-N-(2-
phenylpropan-2-yl)-1H-indazole-3-
carboximide).
SR-19 (Also known as RCS-4) (1-Pentyl-3- 7104 I
[(4-methoxy)-benzoyl] indole).
JWH-018 (also known as AM678) (1-Pentyl-3- 7118 I
(1-naphthoyl)indole).
JWH-122 (1-Pentyl-3-(4-methyl-1- 7122 I
naphthoyl) indole).
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3- 7144 I
tetramethylcyclopropyl)methanone).
JWH-073 (1-Butyl-3-(1-naphthoyl)indole).. 7173 I
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1- 7200 I
naphthoyl)indole).
AM2201 (1-(5-Fluoropentyl)-3-(1- 7201 I
naphthoyl) indole).
JWH-203 (1-Pentyl-3-(2- 7203 I
chlorophenylacetyl) indole).
NM2201, CBL2201 (Naphthalen-1-yl 1-(5- 7221 I
fluoropentyl)-1H-indole-3-carboxylate).
PB-22 (Quinolin-8-yl 1-pentyl-1H-indole-3- 7222 I
carboxylate).
5F-PB-22 (Quinolin-8-yl 1-(5- 7225 I
fluoropentyl)-1H-indole-3-carboxylate).
Alpha-ethyltryptamine.................... 7249 I
Ibogaine................................. 7260 I
CP-47,497 (5-(1,1-Dimethylheptyl)-2- 7297 I
[(1R,3S)-3-hydroxycyclohexyl-phenol).
CP-47,497 C8 Homologue (5-(1,1- 7298 I
Dimethyloctyl)-2-[(1R,3S)3-
hydroxycyclohexyl-phenol).
Lysergic acid diethylamide............... 7315 I
2,5-Dimethoxy-4-(n)- 7348 I
propylthiophenethylamine (2C-T-7).
Marihuana extract........................ 7350 I
Marihuana................................ 7360 I
Tetrahydrocannabinols.................... 7370 I
Parahexyl................................ 7374 I
Mescaline................................ 7381 I
2C-T-2, (2-(4-Ethylthio-2,5- 7385 I
dimethoxyphenyl) ethanamine).
3,4,5-Trimethoxyamphetamine.............. 7390 I
4-Bromo-2,5-dimethoxyamphetamine......... 7391 I
4-Bromo-2,5-dimethoxyphenethylamine...... 7392 I
4-Methyl-2,5-dimethoxyamphetamine........ 7395 I
[[Page 31624]]
2,5-Dimethoxyamphetamine................. 7396 I
JWH-398 (1-Pentyl-3-(4-chloro-1- 7398 I
naphthoyl) indole).
2,5-Dimethoxy-4-ethylamphetamine......... 7399 I
3,4-Methylenedioxyamphetamine............ 7400 I
5-Methoxy-3,4-methylenedioxyamphetamine.. 7401 I
N-Hydroxy-3,4-methylenedioxyamphetamine.. 7402 I
3,4-Methylenedioxy-N-ethylamphetamine.... 7404 I
3,4-Methylenedioxymethamphetamine........ 7405 I
4-Methoxyamphetamine..................... 7411 I
5-Methoxy-N-N-dimethyltryptamine......... 7431 I
Alpha-methyltryptamine................... 7432 I
Bufotenine............................... 7433 I
Diethyltryptamine........................ 7434 I
Dimethyltryptamine....................... 7435 I
Psilocybin............................... 7437 I
Psilocyn................................. 7438 I
5-Methoxy-N,N-diisopropyltryptamine...... 7439 I
N-Ethyl-1-phenylcyclohexylamine.......... 7455 I
1-(1-Phenylcyclohexyl)pyrrolidine........ 7458 I
1-[1-(2-Thienyl)cyclohexyl]piperidine.... 7470 I
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine... 7473 I
N-Ethyl-3-piperidyl benzilate............ 7482 I
N-Methyl-3-piperidyl benzilate........... 7484 I
N-Benzylpiperazine....................... 7493 I
4-MePPP (4-Methyl- 7498 I
alphapyrrolidinopropiophenone).
2C-D (2-(2,5-Dimethoxy-4-methylphenyl) 7508 I
ethanamine).
2C-E (2-(2,5-Dimethoxy-4-ethylphenyl) 7509 I
ethanamine).
2C-H (2-(2,5-Dimethoxyphenyl) ethanamine) 7517 I
2C-I (2-(4-iodo-2,5-dimethoxyphenyl) 7518 I
ethanamine).
2C-C (2-(4-Chloro-2,5-dimethoxyphenyl) 7519 I
ethanamine).
2C-N (2-(2,5-Dimethoxy-4-nitro-phenyl) 7521 I
ethanamine).
2C-P (2-(2,5-Dimethoxy-4-(n)- 7524 I
propylphenyl) ethanamine).
2C-T-4 (2-(4-Isopropylthio)-2,5- 7532 I
dimethoxyphenyl) ethanamine).
MDPV (3,4-Methylenedioxypyrovalerone).... 7535 I
25B-NBOMe (2-(4-bromo-2,5- 7536 I
dimethoxyphenyl)-N-(2-methoxybenzyl)
ethanamine).
25C-NBOMe (2-(4-chloro-2,5- 7537 I
dimethoxyphenyl)-N-(2-methoxybenzyl)
ethanamine).
25I-NBOMe (2-(4-iodo-2,5-dimethoxyphenyl)- 7538 I
N-(2-methoxybenzyl) ethanamine).
Methylone (3,4-Methylenedioxy-N- 7540 I
methylcathinone).
Butylone................................. 7541 I
Pentylone................................ 7542 I
N-Ethylpentylone, ephylone (1-(1,3- 7543 I
benzodioxol-5-yl)-2-(ethylamino)-pentan-
1-one).
[alpha]-PVP (alpha- 7545 I
pyrrolidinopentiophenone).
[alpha]-PBP (alpha- 7546 I
pyrrolidinobutiophenone).
AM-694 (1-(5-Fluoropentyl)-3-(2- 7694 I
iodobenzoyl) indole).
Acetyldihydrocodeine..................... 9051 I
Benzylmorphine........................... 9052 I
Codeine-N-oxide.......................... 9053 I
Cyprenorphine............................ 9054 I
Desomorphine............................. 9055 I
Etorphine (except HCl)................... 9056 I
Codeine methylbromide.................... 9070 I
Dihydromorphine.......................... 9145 I
Difenoxin................................ 9168 I
Heroin................................... 9200 I
Hydromorphinol........................... 9301 I
Methyldesorphine......................... 9302 I
Methyldihydromorphine.................... 9304 I
Morphine methylbromide................... 9305 I
Morphine methylsulfonate................. 9306 I
Morphine-N-oxide......................... 9307 I
Myrophine................................ 9308 I
Nicocodeine.............................. 9309 I
Nicomorphine............................. 9312 I
Normorphine.............................. 9313 I
Pholcodine............................... 9314 I
Thebacon................................. 9315 I
Acetorphine.............................. 9319 I
Drotebanol............................... 9335 I
U-47700 (3,4-dichloro-N-[2- 9547 I
(dimethylamino)cyclohexyl]-N-
methylbenzamide).
AH-7921 (3,4-dichloro-N-[(1- 9551 I
dimethylamino)cyclohexylmethyl]benzamide
)).
MT-45 (1-cyclohexyl-4-(1,2- 9560 I
diphenylethyl)piperazine)).
Acetylmethadol........................... 9601 I
Allylprodine............................. 9602 I
Alphacetylmethadol except levo- 9603 I
alphacetylmethadol.
[[Page 31625]]
Alphameprodine........................... 9604 I
Alphamethadol............................ 9605 I
Benzethidine............................. 9606 I
Betacetylmethadol........................ 9607 I
Betameprodine............................ 9608 I
Betamethadol............................. 9609 I
Betaprodine.............................. 9611 I
Clonitazene.............................. 9612 I
Dextromoramide........................... 9613 I
Diampromide.............................. 9615 I
Diethylthiambutene....................... 9616 I
Dimenoxadol.............................. 9617 I
Dimepheptanol............................ 9618 I
Dimethylthiambutene...................... 9619 I
Dioxaphetyl butyrate..................... 9621 I
Dipipanone............................... 9622 I
Ethylmethylthiambutene................... 9623 I
Etonitazene.............................. 9624 I
Etoxeridine.............................. 9625 I
Furethidine.............................. 9626 I
Hydroxypethidine......................... 9627 I
Ketobemidone............................. 9628 I
Levomoramide............................. 9629 I
Levophenacylmorphan...................... 9631 I
Morpheridine............................. 9632 I
Noracymethadol........................... 9633 I
Norlevorphanol........................... 9634 I
Normethadone............................. 9635 I
Norpipanone.............................. 9636 I
Phenadoxone.............................. 9637 I
Phenampromide............................ 9638 I
Phenoperidine............................ 9641 I
Piritramide.............................. 9642 I
Proheptazine............................. 9643 I
Properidine.............................. 9644 I
Racemoramide............................. 9645 I
Trimeperidine............................ 9646 I
Phenomorphan............................. 9647 I
Propiram................................. 9649 I
1-Methyl-4-phenyl-4-propionoxypiperidine. 9661 I
1-(2-Phenylethyl)-4-phenyl-4- 9663 I
acetoxypiperidine.
Tilidine................................. 9750 I
Acryl fentanyl (N-(1-phenethylpiperidin-4- 9811 I
yl)-N-phenylacrylamide).
Para-Fluorofentanyl...................... 9812 I
3-Methylfentanyl......................... 9813 I
Alpha-Methylfentanyl..................... 9814 I
Acetyl-alpha-methylfentanyl.............. 9815 I
N-(2-fluorophenyl)-N-(1- 9816 I
phenethylpiperidin-4-yl)propionamide.
Acetyl Fentanyl (N-(1-phenethylpiperidin- 9821 I
4-yl)-N-phenylacetamide).
Butyryl Fentanyl......................... 9822 I
Para-fluorobutyryl fentanyl.............. 9823 I
4-Fluoroisobutyryl fentanyl (N-(4- 9824 I
fluorophenyl)-N-(1-phenethylpiperidin-4-
yl)isobutyramide).
2-methoxy-N-(1-phenethylpiperidin-4-yl)-N- 9825 I
phenylacetamide.
Para-chloroisobutyryl fentanyl........... 9826 I
Isobutyryl fentanyl...................... 9827 I
Beta-hydroxyfentanyl..................... 9830 I
Beta-hydroxy-3-methylfentanyl............ 9831 I
Alpha-methylthiofentanyl................. 9832 I
3-Methylthiofentanyl..................... 9833 I
Furanyl fentanyl (N-(1-phenethylpiperidin- 9834 I
4-yl)-N-phenylfuran-2-carboxamide).
Thiofentanyl............................. 9835 I
Beta-hydroxythiofentanyl................. 9836 I
Para-methoxybutyryl fentanyl............. 9837 I
Ocfentanil............................... 9838 I
Valeryl fentanyl......................... 9840 I
N-(1-phenethylpiperidin-4-yl)-N- 9843 I
phenyltetrahydrofuran-2-carboxamide).
Cyclopropyl Fentanyl..................... 9845 I
Cyclopentyl fentanyl..................... 9847 I
Fentanyl related-compounds as defined in 9850 I
21 CFR 1308.11(h).
Amphetamine.............................. 1100 II
Methamphetamine.......................... 1105 II
Lisdexamfetamine......................... 1205 II
Phenmetrazine............................ 1631 II
Methylphenidate.......................... 1724 II
[[Page 31626]]
Amobarbital.............................. 2125 II
Pentobarbital............................ 2270 II
Secobarbital............................. 2315 II
Glutethimide............................. 2550 II
Dronabinol in an oral solution in a drug 7365 II
product approved for marketing by the
U.S. Food and Drug Administration.
Nabilone................................. 7379 II
1-Phenylcyclohexylamine.................. 7460 II
Phencyclidine............................ 7471 II
ANPP (4-Anilino-N-phenethyl-4-piperidine) 8333 II
Phenylacetone............................ 8501 II
1-Piperidinocyclohexanecarbonitrile...... 8603 II
Alphaprodine............................. 9010 II
Anileridine.............................. 9020 II
Cocaine.................................. 9041 II
Codeine.................................. 9050 II
Etorphine HCl............................ 9059 II
Dihydrocodeine........................... 9120 II
Oxycodone................................ 9143 II
Hydromorphone............................ 9150 II
Diphenoxylate............................ 9170 II
Ecgonine................................. 9180 II
Ethylmorphine............................ 9190 II
Hydrocodone.............................. 9193 II
Levomethorphan........................... 9210 II
Levorphanol.............................. 9220 II
Isomethadone............................. 9226 II
Meperidine............................... 9230 II
Meperidine-intermediate-A................ 9232 II
Meperidine intermediate-B................ 9233 II
Meperidine intermediate-C................ 9234 II
Metazocine............................... 9240 II
Methadone................................ 9250 II
Methadone intermediate................... 9254 II
Metopon.................................. 9260 II
Dextropropoxyphene, bulk (non-dosage 9273 II
forms).
Morphine................................. 9300 II
Oripavine................................ 9330 II
Thebaine................................. 9333 II
Dihydroetorphine......................... 9334 II
Levo-alphacetylmethadol.................. 9648 II
Oxymorphone.............................. 9652 II
Noroxymorphone........................... 9668 II
Phenazocine.............................. 9715 II
Thiafentanil............................. 9729 II
Piminodine............................... 9730 II
Racemethorphan........................... 9732 II
Racemorphan.............................. 9733 II
Alfentanil............................... 9737 II
Remifentanil............................. 9739 II
Sufentanil............................... 9740 II
Carfentanil.............................. 9743 II
Tapentadol............................... 9780 II
Bezitramide.............................. 9800 II
Fentanyl................................. 9801 II
Moramide-intermediate.................... 9802 II
------------------------------------------------------------------------
[[Page 31627]]
The company plans to import analytical reference standards for
distribution to its customers for research and analytical purposes.
Placement of these drug codes onto the company's registration does not
translate into automatic approval of subsequent permit applications to
import controlled substances. Approval of permit applications will
occur only when the registrant's business activity is consistent with
what is authorized in 21 U.S.C. 952(a)(2). Authorization will not
extend to the import of FDA approved or non-approved finished dosage
forms for commercial sale.
Dated: June 18, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-14026 Filed 7-1-19; 8:45 am]
BILLING CODE 4410-09-P
